Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Alessandra Messikommer"'
Autor:
Katja Seipel, Alexandre Theocharides, Bruktawit Maru, Thomas Pabst, Maureen McKeague, Peter J. M. Valk, Nathan W. Luedtke, Alessandra Messikommer
SUMMARYFor nearly 50 years, translational research studies aimed at improving chemotherapy-induced killing of cancer cells have focused on the induction of apoptosis. Here we show that a PARP-1-mediated programmed cell death mechanism “parthanatos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b9e18174171c7986b9deb29ab5cb243e
https://doi.org/10.1101/2021.05.24.445484
https://doi.org/10.1101/2021.05.24.445484
Autor:
Nathan W. Luedtke, Stephen Byrne, Peter J. M. Valk, Alessandra Messikommer, Thomas Pabst, Katja Seipel
Publikováno v:
ACS Pharmacol Transl Sci
ACS Pharmacology and Translational Science, 3(6), 1225-1232. American Chemical Society
ACS Pharmacology and Translational Science, 3(6), 1225-1232. American Chemical Society
[Image: see text] Nucleosides and their analogues constitute an essential family of anticancer drugs. DNA has been the presumptive target of the front-line prodrug for acute myeloid leukemia (AML), cytarabine (ara-C), since the 1980s. Here, the biomo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51757f25b68c6b0b9b1a62bd546f0198
https://pubmed.ncbi.nlm.nih.gov/33344899
https://pubmed.ncbi.nlm.nih.gov/33344899
Autor:
Alessandra Messikommer, Nathan W. Luedtke, Stella M. K. Glasauer, Miriam H. Paulisch, Therese Triemer, Jawad Alzeer
Publikováno v:
Proceedings of the National Academy of Sciences. 115
Many drugs require extensive metabolism en route to their targets. High-resolution visualization of prodrug metabolism should therefore utilize analogs containing a small modification that does not interfere with its metabolism or mode of action. In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cab6976a5b22deda426dd62ebec886a0
https://doi.org/10.1073/pnas.1714790115
https://doi.org/10.1073/pnas.1714790115
Autor:
Martin Pruschy, Van Vuong, Alessandra Messikommer, Matthias Guckenberger, Heidi Lane, Katarzyna J. Nytko, Angela Broggini-Tenzer, Felix Bachmann, Ashish Sharma
Publikováno v:
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 124(3)
Background and purpose Resistance to microtubule targeting agents (MTA) represents a major drawback in successful cancer therapy with MTAs. Here we investigated the combined treatment modality of the novel MTA BAL101553 in combination with radiothera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::467ae64e13bc6044789808203f80b289
https://pubmed.ncbi.nlm.nih.gov/28797699
https://pubmed.ncbi.nlm.nih.gov/28797699